Digital health company. Quaterly due next week. Commercialisation rolling out with the launch due of sleep apnoea App on IOS and Play store for Android devices. Partnered with telehealth provider Phoenix health and Coviu and expected to be available for use in 4 to 6 weeks. TGA approval for ResAppDx-EU, It has the ability to identify lower respiratory tract disease, pneumonia, COPD exacerbations and asthma exacerbations. ResAppDx-EU is now approved for use by clinicians to differentially diagnose respiratory diseases in children and adults in both Europe (CE Mark) and Australia. ResAppDx-EU provides a fast and accurate point-of-care diagnosis for the most common acute respiratory diseases, and runs on a smartphone, with no additional hardware or accessories required.
CEO Tony Keating has said in an interview 22/04/20 ‘We are exploring ways of identifying the virus itself through cough, but also see an immediate opportunity to assist in managing patients with COVID-19 remotely, by identifying mild patients (i.e. patients where the disease has not progressed to a lung infection) and keeping them at home, reducing the load on hospitals and other facilities.’
